Evaluation of peripheral and autonomic nervous systems dysfunctions in patients with Parkinson’s disease

Table 1 Age, sex, disease duration, severity, and Scales for Outcomes in Parkinson’s disease—autonomic dysfunction among studied groups

	Control subjects	Drug-naïve patients with PD	Patients with PD on dopaminergic drugs	p-value	Tukey test
Age in years	57.5 ± 4.52	57.8 ± 3.52	59.2 ± 2.26	0.35	P1:0.77 P2:0.351 P3:0.354
Sex (male)	11	12	10	0.12	P1:0.144 P2:0.122 P3:0.121
Disease duration (years)		1.2 ± 0.32	3.7 ± 1.7	0.001
MDS-UPDRS		50.78 ± 14.12	70.71 ± 18.87	0.001
Hoehn and Yahr		1.3 ± 0.5	2.4 ± 0.7	0.01
SCOPA-AUT	6.3 ± 1.5	9.5 ± 0.98	12.5 ± 1.5	0.001	P1:0.001 P2:0.001 P3:0.001

MDS-UPDRS (MDS-Unified Parkinson’s Disease Rating Scale). SCOPA-AUT (Scales for Outcomes in Parkinson’s disease—Autonomic Dysfunction). P1 (control versus drug-naïve patients with PD). P2 (control versus patients on dopaminergic drugs). P3 (drug-naïve patients with PD versus patients on dopaminergic drugs)